Tvardi Therapeutics Inc. (NASDAQ:TVRD) stock fell in Thursday’s premarket session, as investors appeared to take profits after the stock more than doubled since Tuesday following positive Phase 1 data for its investigational therapy TTI-109.
The company said the Phase 1 study confirmed the rapid conversion of TTI-109 to TTI-101 and showed meaningful reductions in disease-relevant STAT3-driven immune cell populations.
Tvardi plans to advance TTI-109 into STAT3-driven dermatologic and gastrointestinal diseases, subject to additional funding.
According to the company, TTI-109 is a phosphate prodrug of TTI-101 designed to improve drug delivery and tolerability while preserving the same mechanism of action.
The study showed TTI-109 converted to TTI-101 within two hours and achieved nearly identical plasma exposure at molar-equivalent doses, supporting the prodrug strategy.
Tvardi Therapeutics Technical Analysis: Trend, RSI And Key Levels
Currently, Tvardi Therapeutics is trading at $4.56, significantly above its 20-day simple moving average (SMA) of $2.53, indicating a bullish short-term trend. However, the stock is 31.7% below its 200-day SMA of $6.60, suggesting a bearish long-term outlook.
The Relative Strength Index (RSI) stands at 77.04, indicating that the stock is in overbought territory, which could lead to a price correction in the near term.
- Key Resistance: $6.00 — a psychological level that traders may watch closely.
- Key Support: $4.00 — a nearby level where buyers previously stepped in.
Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price forecast of $8.00. Recent analyst moves include:
- Raymond James: Upgraded to Outperform (Target $10.00) (July 8)
- BTIG: Buy (Maintains forecast to $15.00) (July 7)
- HC Wainwright & Co.: Initiated with Buy (Forecast $9.00) (June 8)
TVRD Stock Price Activity: Tvardi Therapeutics shares were down 8.20% at $4.59 during premarket trading on Thursday, according to Benzinga Pro data.
Photo via Shutterstock
Recent Comments